The effect of Resveratrol on the pharmacokinetic profile of tofacitinib and the underlying mechanism
- 9 February 2023
- journal article
- research article
- Published by Elsevier in Chemico-Biological Interactions
- Vol. 374, 110398
Abstract
No abstract availableKeywords
Funding Information
- National Key Research and Development Program of China (2020YFC2008301)
- National Natural Science Foundation of China (82104297)
- Wenzhou Municipal Science and Technology Bureau (Y20220898)
This publication has 17 references indexed in Scilit:
- Functional characterization of 27 CYP3A4 protein variants to metabolize regorafenib in vitroBasic & Clinical Pharmacology & Toxicology, 2019
- Tofacitinib for the treatment of rheumatoid arthritis: an updateExpert Review of Clinical Immunology, 2019
- Inhibitory effect of resveratrol on the pharmacokinetic of ibrutinib by UPLC–MS/MSDrug Development and Industrial Pharmacy, 2019
- Functional characterization of 21 CYP3A4 variants on amiodarone metabolismin vitroXenobiotica, 2018
- Tofacitinib: A Review in Rheumatoid ArthritisDrugs, 2017
- Systematic Screening forCYP3A4Genetic Polymorphisms in a Han Chinese PopulationPharmacogenomics, 2017
- The effect of resveratrol on pharmacokinetics of aripiprazolein vivoandin vitroXenobiotica, 2015
- Functional Gene Variants of CYP3A4Clinical Pharmacology & Therapeutics, 2014
- Cytochrome P450 enzymes in drug metabolism: Regulation of gene expression, enzyme activities, and impact of genetic variationPharmacology & Therapeutics, 2013
- Resveratrol, a red wine constituent, is a mechanism-based inactivator of cytochrome P450 3A4Life Sciences, 2000